Literature DB >> 12626563

Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP.

Eleni E Magira1, Miltiadis Papaioakim, Irving Nachamkin, Arthur K Asbury, Chun Y Li, Tony W Ho, John W Griffin, Guy M McKhann, Dimitri S Monos.   

Abstract

Guillain-Barré syndrome (GBS), an acute, immune-mediated paralytic disorder affecting the peripheral nervous system, is the most common cause of acute flaccid paralysis in the post-polio era. GBS is classified into several subtypes based on clinical and pathologic criteria, with acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) being the most common forms observed. To better understand the pathogenesis of GBS and host susceptibility to developing the disease, the distribution of HLA class II Ags along with the seroreactivity to Campylobacter jejuni were investigated in a population of GBS patients from northern China. Using DNA-based typing methods, 47 patients with AMAN, 25 patients with AIDP, and 97 healthy controls were studied for the distribution of class II alleles. We found that the DQ beta RLD(55-57)/ED(70-71) and DR beta E(9)V(11)H(13) epitopes were associated with susceptibility to AIDP (p = 0.009 and p = 0.004, respectively), and the DQ beta RPD(55-57) epitope was associated with protection (p = 0.05) from AIDP. These DQ beta/DR beta positional residues are a part of pockets 4 (DQ beta 70, 71, DR beta 13), 6 (DR beta 11), and 9 (DQ beta 56, 57, DR beta 9); have been demonstrated to be important in peptide binding and T cell recognition; and are associated with other diseases that have a pathoimmunological basis. Class II HLA associations were not identified with AMAN, suggesting a different immunological mechanism of disease induction in the two forms of GBS. These findings provide immunogenetic evidence for differentiating the two disease entities (AMAN and AIDP) and focuses our attention on particular DR beta/DQ beta residues that may be instrumental in understanding the pathophysiology of AIDP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626563     DOI: 10.4049/jimmunol.170.6.3074

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Neurologic symptoms associated with raising poultry and swine among participants in the Agricultural Health Study.

Authors:  Meghan F Davis; Freya Kamel; Jane A Hoppin; Michael C R Alavanja; Laura Beane Freeman; Gregory C Gray; Kenrad Nelson; Ellen Silbergeld
Journal:  J Occup Environ Med       Date:  2011-02       Impact factor: 2.162

2.  Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

Authors:  L Schirmer; V Worthington; U Solloch; V Loleit; V Grummel; N Lakdawala; D Grant; R Wassmuth; A H Schmidt; F Gebhardt; T F M Andlauer; J Sauter; A Berthele; M P Lunn; Bernhard Hemmer
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

3.  Immunoglobulin KM allotypes are associated with the prevalence of autoantibodies to GD1a ganglioside, but not with susceptibility to the disease, in Japanese patients with Guillain-Barré syndrome.

Authors:  Janardan P Pandey; Michiaki Koga; Nobuhiro Yuki
Journal:  Neurogenetics       Date:  2005-10-29       Impact factor: 2.660

Review 4.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

Review 5.  Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

Authors:  I Steiner; G Rosenberg; I Wirguin
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 6.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

7.  Comparison of Campylobacter jejuni isolates implicated in Guillain-Barré syndrome and strains that cause enteritis by a DNA microarray.

Authors:  Edward E Leonard; Lucy S Tompkins; Stanley Falkow; Irving Nachamkin
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 8.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

Review 9.  Guillain-Barré syndrome and variants.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-02-19       Impact factor: 3.806

10.  Comparative genotyping of Campylobacter jejuni strains from patients with Guillain-Barré syndrome in Bangladesh.

Authors:  Zhahirul Islam; Alex van Belkum; Jaap A Wagenaar; Alison J Cody; Albert G de Boer; Helen Tabor; Bart C Jacobs; Kaisar A Talukder; Hubert P Endtz
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.